Dr Ida Sue Baron, PHD | |
1830 Town Center Dr, Reston, VA 20190-3292 | |
(301) 340-2119 | |
(301) 340-2119 |
Full Name | Dr Ida Sue Baron |
---|---|
Gender | Female |
Speciality | Clinical Neuropsychologist |
Location | 1830 Town Center Dr, Reston, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1225255102 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Ida Sue Baron, PHD 10116 Weatherwood Ct, Potomac, MD 20854-2173 Ph: (301) 340-2119 | Dr Ida Sue Baron, PHD 1830 Town Center Dr, Reston, VA 20190-3292 Ph: (301) 340-2119 |
News Archive
New UCLA research identifies several factors influencing how people of color in Los Angeles County are making decisions about COVID-19 vaccination.
Long-term supplementation with dietary antioxidants has beneficial effects on sugar and fat metabolism, blood pressure and arterial flexibility in patients with multiple cardiovascular risk factors. Researchers writing in BioMed Central's open access journal Nutrition and Metabolism report these positive results in a randomized controlled trial of combined vitamin C, vitamin E, coenzyme Q10 and selenium capsules.
Recently, researchers have observed a disturbing trend in neonatal units across the country: doctors prescribing Reglan - also known by its generic name, metoclopramide - to treat premature infants. This alarming development has raised serious concerns from many consumer safety advocates, particularly because the drug was never approved for use in infants.
How do individual cells or proteins react to changing pH levels? Researchers at the MESA+ Institute for Nanotechnology at the University of Twente have developed a technique for 'gently' adjusting pH: in other words, without damaging biomolecules. This should soon allow them to measure the activity of a single enzyme as a function of pH.
Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.
› Verified 2 days ago